Biobanks Market

• In July 2023, Sweden implemented a revised Biobank Act, representing a contemporary update to the existing legislation. While upholding its primary goal of regulating the collection, storage, and ethical usage of identifiable human biological material for approved purposes, the new act aims to address and clarify uncertainties present in the original 2003 law. This modernization effort is designed to improve the understanding and interpretation of the regulations governing biobanking practices in Sweden.

• In June 2023, Denmark, Lithuania, and Switzerland received official confirmation of their membership in the Biobanking and BioMolecular resources Research Infrastructure – European Research Infrastructure Consortium (BBMRI-ERIC). Lithuania and Switzerland transitioned from their previous status as Observers to achieving full Membership, while Denmark has newly joined as an Observer.

In this report, the Biobanks Market has been segmented by Media, Services, Application, and Geography.

Biobanks Market, Segmentation by Media

The Biobanks Market has been segmented by Media into Optimized Media and Non-Optimized Media.

Optimized Media

The Optimized Media segment dominates the biobanks market, accounting for more than 60% of the overall share. It is preferred for its ability to maintain the viability and integrity of biological samples over extended periods. Increased adoption in advanced fields such as genomic research, clinical trials, and personalized medicine is boosting its growth. Moreover, its compatibility with automated biobanking systems enhances its scalability and efficiency.

Non-Optimized Media

The Non-Optimized Media segment, contributing around 40%, remains relevant in settings where cost constraints exist or short-term sample storage is sufficient. Though it lacks the reliability of optimized media, it is still used in many academic and research laboratories. However, as the focus shifts toward long-term sample preservation and data reproducibility, its market share is expected to decline.

Biobanks Market, Segmentation by Bio Specimen Type

The Biobanks Market has been segmented by Specimen Type Organs and Stem Cells

The Organs segment contributes about 40% to the biobanks market, supported by its application in transplantation, toxicological studies, and medical research. With advancements in organ preservation and storage protocols, this segment is crucial for research in disease progression and drug development. Its relevance is growing in the context of personalized healthcare and translational medicine.

Accounting for nearly 60% of the biobanks market, the Stem Cells segment is the most dominant due to its wide-ranging applications in regenerative medicine, oncology, and neurodegenerative disorder research. The growing number of clinical trials and government support for stem cell banking have fueled rapid expansion, positioning this segment as a key driver of market growth.

Biobanks Market, Segmentation by Services

The Biobanks Market has been segmented by Services into Human Tissue Biobanking, Stem Cell Biobanking, Cord Banking, DNA/RNA Biobanking, and Others.

Holding a 30% market share, Human Tissue Biobanking plays a critical role in supporting research related to drug discovery, oncology, and personalized treatments. The growing prevalence of chronic and rare diseases, especially cancers, is driving the demand for high-quality tissue samples for clinical and translational research.

With a commanding 35% share, Stem Cell Biobanking is a key segment, propelled by increased interest in regenerative medicine and clinical trial applications. Rising awareness of stem cell therapies for treating degenerative disorders and autoimmune diseases is accelerating growth in this area.

Cord Banking constitutes around 15% of the market, supported by advancements in cord blood preservation and its applications in treating inherited and hematologic conditions. The segment benefits from increasing education among expectant parents about the long-term medical benefits of cord blood storage.

Contributing approximately 12%, the DNA/RNA Biobanking segment is expanding rapidly due to the surge in genomic research, biomarker studies, and population-wide health studies. It is instrumental in supporting the rise of precision medicine and genetic testing solutions.

The Others category, holding the remaining 8%, includes storage of proteins, microbes, and plasma, which are essential for epidemiological and environmental health research. Though smaller in share, it remains vital for a wide array of interdisciplinary scientific studies.

Biobanks Market, Segmentation by Application

The Biobanks Market has been segmented by Application into Regenerative Medicine, Drug Discovery, and Disease Research.

Representing about 40% of the total market, Regenerative Medicine is the leading application segment in the biobanks market. The segment’s growth is driven by increasing reliance on stem cell therapies, tissue regeneration, and advanced cellular therapies. The demand for preserved biospecimens is surging due to their vital role in personalized medical treatments and clinical trials.

Comprising roughly 35% of the market, the Drug Discovery segment benefits significantly from the availability of biobanked samples for target identification, validation, and drug efficacy testing. As pharmaceutical and biotech companies increase investments in R&D pipelines, biobanks are becoming essential in the preclinical and clinical phases of drug development.

With a market share of nearly 25%, Disease Research remains a critical application area. Biobanks provide essential biospecimens that facilitate research in chronic diseases, rare disorders, and public health epidemiology. Their role in advancing genomic studies and understanding disease etiology continues to enhance their value in this segment.

Biobanks Market, Segmentation by Geography

In this report, the Biobanks Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Biobanks Market Share (%), by Geographical Region

Holding over 40% of the global market, North America leads the biobanks landscape, largely due to its robust healthcare infrastructure, government funding, and genomic research initiatives. The United States stands out with a strong network of biorepositories supporting advanced biomedical studies.

With a market share of nearly 30%, Europe remains a significant hub for biobanking activities. The region benefits from a well-coordinated ecosystem, backed by EU-funded research collaborations, stringent biobanking standards, and growing interest in precision medicine.

Asia Pacific is emerging as a high-growth region, capturing around 18% of the market. The rise in clinical trials, coupled with increasing investments in biotechnology and personalized therapies, is accelerating biobank development across countries like China, India, and Japan.

Accounting for about 7% of the global share, the Middle East and Africa region is gradually strengthening its biobanking capabilities. Efforts to combat genetic and infectious diseases are driving interest in biospecimen storage and genomic research.

Latin America currently holds close to 5% of the biobanks market. The region is making steady progress, with countries investing in public health research and biotechnological advancements, creating new opportunities for biobank integration.